EVGN (Evogene) Altman Z2-Score: -53.20 (As of Jul. 01, 2026)


EVGN Evogene Ltd EVGN
34 GF Score
Price $0.43
GF Value $0.45
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Evogene Altman Z2-Score?

Evogene EVGN +1.74% 34 Altman Z2-Score is -53.20 as of Jul. 01, 2026. GuruFocus rates EVGN with a GF Score™ of 34/100 and a GF Value™ of $0.45 (Fairly Valued). The stock has 7 warning signs investors should review. Among 1,394 Biotechnology companies, Evogene ranks worse than 86.37% on this metric.

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Warning Sign:

Evogene has a Altman Z2-Score of -53.20, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Evogene's Altman Z2-Score or its related term are showing as below:

EVGN' s Altman Z2-Score Range Over the Past 10 Years
Min: -53.2   Med: -2.45   Max: 14.58
Current: -53.2

During the past 13 years, Evogene's highest Altman Z2-Score was 14.58. The lowest was -53.20. And the median was -2.45.


Evogene  (NAS:EVGN) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Evogene Altman Z2-Score Related Terms


Evogene Altman Z2-Score Historical Data

* Premium members only.

The historical data trend for Evogene's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evogene Altman Z2-Score Chart

Evogene Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Altman Z2-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.83 -11.99 -15.21 -24.37 -46.45

Evogene Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -28.82 -26.62 -32.53 -46.45 -53.20

EVGN vs VRTX, REGN, ALNY: Altman Z2-Score Comparison

For the Biotechnology subindustry, Evogene's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evogene Altman Z2-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evogene's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Evogene's Altman Z2-Score falls into.


EVGN
34GF Score
Evogene Ltd EVGN
Altman Z2-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Evogene Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Evogene's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.5348+3.26*-16.0701+6.72*-0.6026+1.05*-0.2556
=-53.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2026:
Total Assets was $17.95 Mil.
Total Current Assets was $14.96 Mil.
Total Current Liabilities was $5.36 Mil.
Retained Earnings was $-288.43 Mil.
Pre-Tax Income was 0 + -5.338 + -2.728 + -2.443 = $-10.51 Mil.
Interest Expense was 0 + 1.384 + -0.453 + -0.624 = $0.31 Mil.
Total Liabilities was $9.96 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(14.963 - 5.364)/17.948
=0.5348

X2=Retained Earnings/Total Assets
=-288.426/17.948
=-16.0701

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-10.509 - 0.307)/17.948
=-0.6026

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(-2.545 - 0)/9.958
=-0.2556

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Evogene has a Altman Z2-Score of -53.20 indicating it is in Distress Zones.

Frequently Asked Questions Learn more about Altman Z2-Score →
What does a Altman Z2-Score of -53.20 mean?
Evogene (EVGN) has a Altman Z2-Score of -53.20 as of Jul. 01, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Evogene and its competitors. According to the industry distribution chart, Evogene ranks #1204 out of 1394 companies in the Biotechnology industry, placing it in the top 86.4%.
Is Evogene's Altman Z2-Score too high?
Evogene's current Altman Z2-Score is -53.20. Based on the distribution chart, Evogene ranks #1204 out of 1394 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Evogene has a GF Score™ of 34/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Evogene's Altman Z2-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Evogene ranks #1204 out of 1394 companies for Altman Z2-Score. This places Evogene in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Biotechnology company?
A good Altman Z2-Score depends on the Biotechnology industry context. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Evogene and its competitors. Evogene's current Altman Z2-Score is -53.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evogene stock overvalued right now?
Based on GuruFocus' analysis, Evogene (EVGN) is currently considered Fairly Valued. The stock's GF Value™ is $0.45, compared to a current price of $0.43 — trading 5% below its estimated fair value. The current Altman Z2-Score is -53.20. Evogene's overall GF Score™ is 34/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Evogene (EVGN), the current Altman Z2-Score is -53.20 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Evogene (EVGN) Overvalued in 2026?

Based on GuruFocus' analysis, Evogene stock appears to be undervalued. The current stock price of $0.43 is trading 5% below its estimated GF Value™ of $0.45. GuruFocus considers Evogene to be Fairly Valued.

Key valuation signals for EVGN:

  • Altman Z2-Score: -53.20
  • GF Value™: $0.45 vs. price of $0.43 (5% below fair value)
  • GF Score™: 34/100 with 7 warning signs

No single metric tells the full story. See the EVGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Evogene Business Description

Other Exchanges EVGN:Israel
Address 13 Gad Feinstein Street, Park Rehovot, Ness Ziona, Rehovot, ISR, 7638517
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the industrial segment, followed by Agriculture.
34GF Score

Get the complete analysis for EVGN

Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.43
Price
$0.45
GF Value